Latest Targeted therapy Stories
Offers Potential New Therapy for Difficult-to-Treat Triple Negative Breast Cancer Philadelphia, PA (PRWEB) May 22, 2014 A study from the Department of
RnRMarketResearch.com offers "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options" research report in its
RnRMarketResearch.com adds "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies" to its store. DALLAS,
First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/
Improvements in Key Efficacy Endpoints, Especially Overall Survival, are Pivotal Drivers for Prescribing, According to a New Report from Decision Resources Group BURLINGTON, Mass., April 29,
- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that
LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Researchers have located a biomarker that they believe could help explain why many of the medications used to treat lung, breast and pancreatic cancers also promote drug resistance and ultimately cause tumors to form in patients.
Improved Overall Survival and Delayed Disease Progression are the Greatest Unmet Needs in this Population, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014
DUBLIN, April 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in) has announced the addition of a new report
- A poem in which the author retracts something said in an earlier poem.